Pages that link to "Q34481742"

The following pages link to Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts (Q34481742):

Displaying 13 items.

• Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir (Q33365948) (← links)
• Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants (Q35558815) (← links)
• Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients (Q36093289) (← links)
• Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel? (Q36748051) (← links)
• Prodrugs: design and clinical applications. (Q37064858) (← links)
• Bioactive natural products with anti-herpes simplex virus properties (Q38523078) (← links)
• Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation (Q42022232) (← links)
• Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides (Q42687324) (← links)
• Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. (Q44377380) (← links)
• Solubility and dissolution enhancement strategies: current understanding and recent trends (Q51020710) (← links)
• Chapter 26. To market, to market - 2001 (Q57480824) (← links)
• Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients with Valganciclovir (Q57763738) (← links)
• Infectious Esophagitis (Q78772772) (← links)